RADNOR, Pennsylvania, United States, October 2025 – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Gregory L. Summe, current independent director, will serve as the Company’s next Chairman of the Board, beginning January 1, 2026. Jonathan Peacock has informed the Board of his decision to step down as Chairman and as a director at the end of 2025, after nearly nine years of dedicated service to the Board.
Since joining the Avantor Board in 2020, Mr. Summe has served as Chairman of the Nominating and Governance Committee and as a member of the Compensation Committee. Mr. Summe is a highly experienced CEO and Board member in the Tools and Life Sciences sector.
Mr. Peacock said, “It has been a privilege to serve as Avantor’s Chairman and to work alongside my Board colleagues in managing the Company’s transition to a new CEO and in building its position as a Life Sciences leader. With Emmanuel Ligner as our new CEO and with the addition of Greg Lucier to our Board, this is the right moment for new Board leadership. The Avantor Board comprises talented, experienced leaders with a wide range of backgrounds and expertise in life sciences. I am confident that with their guidance and Emmanuel’s leadership, Avantor will realize its potential and deliver strong shareholder returns.”
“Having served on the Board for the past five years, I’ve seen firsthand the talent across Avantor,” said Mr. Summe. “I look forward to working closely with my fellow Board members, Emmanuel, and the entire leadership team as we continue executing our strategy to deliver growth and profitability across the business.”
Mr. Summe continued, “On behalf of the Board, I also want to express our deep appreciation to Jon for his strong leadership of the Board, managing the transition to our new CEO, and his unwavering commitment to Avantor.”
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development, and production activities at more than 300,000 customer locations in 180 countries.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
